MGMT: its role in cancer aetiology and cancer therapeutics

By Stanton L. Gerson. Nature Reviews. Cancer, 2004

825 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/8901b8280834f3fc901f22e18e3bec1b5dc5a95c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael Weller
2. Guido Reifenberger
3. B. Kaina
4. W. Roos

In Molecular Biology

1. B. Kaina
2. W. Roos
3. Elias K. Michaelis
4. Simone Fulda

In Oncology

1. B. Kaina
2. W. Roos
3. Elias K. Michaelis

Citations in the corpus

• DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. (2013, background): “OMeG does not block DNA synthesis significantly, it causes the formation of GC to AT point mutations after two rounds of DNA replication and, consequently, is a DNA adduct [14] important for cancer induction [15] and cancer progression [16].”
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “Tumors frequently exhibit higher levels of expression than do their tissue of origin.(1)”